Neurocrine Biosciences, Inc. (NBIX) Posts Q1 Loss of 17c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Neurocrine Bio. (NBIX) PT Trimmed at Jeffereis, 'Buy' Maintained
May 1, 2014 8:03 AM EDTJefferies analyst Thomas Wei trimmed his price target on Neurocrine Bio. (NASDAQ: NBIX) to $21.00 (from $23.00) but maintained a Buy rating following the company's Q1 update.
Wei comments, "On its 1Q14 call, NBIX focused on its upcoming FDA meeting and subsequent initiation... More



